Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | CFB | P00751 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628943 | 0.79 | KDM4E (0.35) | KDM4EALDH1A1POLBERBB2CFB | |
| SCHEMBL16382707 | 0.79 | AXL (0.41) | PRKCIKDM4EALDH1A1POLBERBB2 | |
| SCHEMBL1473045 | 0.77 | CFB (0.40) | KDM4ECFB | |
| SCHEMBL31275318 | 0.76 | PRKCI (0.42) | PRKCIDYRK1AAHRCFB | |
| SCHEMBL2211568 | 0.76 | PRKCI (0.42) | PRKCIDYRK1AAHRCFB | |
| SCHEMBL31639077 | 0.74 | NOS1 (0.34) | KDM4EALDH1A1POLB | |
| SCHEMBL31279052 | 0.73 | DYRK1A (0.44) | PRKCIDYRK1AAHR | |
| SCHEMBL2674588 | 0.73 | PIK3C3 (0.41) | PRKCIAHRCFB | |
| SCHEMBL1763755 | 0.73 | DYRK1A (0.44) | PRKCIDYRK1AAHR | |
| SCHEMBL25680888 | 0.73 | PRKCI (0.40) | PRKCIAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137329-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567339-B2 | Primary carboxamides as BTK inhibitors | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3013337-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | Abbvie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| CN-105530932-A | Primary carboxamides as BIK inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| WO-2014210255-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210255-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | PRKCI 227/4885KDM4E 591/4885ALDH1A1 2557/4885 |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | PRKCI 227/4885KDM4E 591/4885ALDH1A1 2557/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | PRKCI 2950/4885KDM4E 551/4885ALDH1A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.